Record drug shortages (≥216 active in the US in 2025) expose limited end-to-end visibility, motivating AI-driven early risk detection and coordinated mitigation across fragmented networks.

BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years. In the final part of Pharmaceutical Commerce’s conversation with Will ...

Jessica Lovett explains the importance of being connected to the broader access ecosystem and leveraging partnerships that can provide global insight and intelligence. In the final part of ...

The pharmaceutical supply chain is rapidly entering its “AI-first” phase. Control towers predict delays, reroute shipments, ...

Acting commissioner Kyle Diamantas assumes interim control, prolonging uncertainty until a Senate-confirmed commissioner is installed and governance stabilizes. Elevated leadership churn and perceived ...

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle. In the second part of Pharmaceutical Commerce’s conversation with Tommy Bramley, ...

Regulatory scrutiny, geopolitical uncertainty, new patient populations, and novel modalities are converging to drive structural change in where therapies are made and how they flow through global ...

President Trump’s Most Favored Nation (MFN) drug pricing proposals are awaiting approval by the U.S. Congress. Passage of the ...

Sources familiar with White House deliberations suggest Makary’s departure is imminent, though neither the White House nor HHS has confirmed or named a successor. Makary’s tenure aligned FDA with MAHA ...